GTS Securities’s VanEck Pharmaceutical ETF PPH Stock Holding History

GTS Securities’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.04M	Sell	36,942 -165,483	-82%	-$17.1M	0.09%	135
2026 Q1	$21M	Buy	+202,425	New	+$21.6M	0.74%	28
2025 Q4	–	Sell	-3,762	Closed	-$340K	–	1695
2025 Q3	$340K	Buy	+3,762	New	+$330K	0.01%	958
2024 Q3	–	Sell	-4,341	Closed	-$397K	–	4354
2024 Q2	$397K	Hold	4,341	–	–	﹤0.01%	2891
2024 Q1	$394K	Hold	4,341	–	–	﹤0.01%	2773
2023 Q4	$353K	Buy	+4,341	New	+$340K	﹤0.01%	3071

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

GTS Securities's PPH Position: Q2 2026 in Review

GTS Securities reduced its VanEck Pharmaceutical ETF (PPH) stake by 82% in Q2 2026, selling an estimated $17.1M and leaving 36,942 shares worth $4.04M. The position accounts for 0.09% of the portfolio, ranked #135.

GTS Securities first reported a position in PPH in Q4 2023 and has held it in 6 quarters since. The position peaked at $21M in Q1 2026. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

GTS Securities held 36,942 shares of VanEck Pharmaceutical ETF worth $4.04M as of Q2 2026.
GTS Securities sold 165,483 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $17.1M.
VanEck Pharmaceutical ETF made up 0.09% of GTS Securities's portfolio in Q2 2026, its #135 holding.
GTS Securities first reported a position in VanEck Pharmaceutical ETF in Q4 2023 and has held it in 6 quarters since.
GTS Securities's VanEck Pharmaceutical ETF position peaked at $21M in Q1 2026.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.